ILMNILMN
US • —
$175.83
P/E
31.83
PEG
—
FCF Yield
—
Rev Growth YoY
+1.3% YoY
Gross Margin
66.7%
Health Score
6/10
D/E Ratio
0.73
Confidence
LOW
Business Snapshot
Illumina develops and commercialises integrated systems for genetic analysis, primarily selling sequencing instruments, consumables, and informatics solutions. It operates as the dominant leader in the DNA sequencing market, holding a commanding share against a limited set of competitors. Market capitalisation data is unavailable, though reported free cash flow is also absent, preventing a full assessment of financial scale. The company's defining characteristic is its entrenched technological moat in the gene-sequencing industry, supported by a large installed base that drives recurring consumable revenue.
Financial Health
Gross margin of 66.7% highlights significant pricing power and a high-value product mix, though a prior-year comparison is unavailable. Net margin stands at 19.4%, indicating solid operational efficiency...
Risk Assessment
- VALUATION — P/E of 31.83x trades at a 45% premium to the sector average of 22x, demanding high future growth.
- EARNINGS QUALITY — Although 4 of 4 recent quarters beat estimates, the lack of reported earnings growth data raises questions about the quality of those beats.
- REVENUE DECELERATION — Revenue growth of just 1.3% YoY is extremely modest for a company with an expensive valuation multiple.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- FCF / CASH BURN — Free cash flow is not reported in the data, leaving a critical gap in assessing the company's ability to self-fund.
- INSIDER ACTIVITY — 0 insider buys versus 9 sells over the last 90 days is a notable bearish signal from those most familiar with the business....
Gross margin of 66.7% highlights significant pricing power and a high-value product mix, though a prior-year comparison is unavailable. Net margin stands at 19.4%, indicating solid operational efficiency. The debt/equity ratio of 0.73x is manageable, and a current ratio of 2.08x reflects ample short-term liquidity. Return on equity of 34.0% is exceptionally strong, showing highly effective capital deployment. Free cash flow and FCF yield are not available in the data, preventing a complete picture of cash generation quality. Overall, the balance sheet appears healthy, supporting ongoing reinvestment in research and development without immediate financing risk.
- VALUATION — P/E of 31.83x trades at a 45% premium to the sector average of 22x, demanding high future growth. - EARNINGS QUALITY — Although 4 of 4 recent quarters beat estimates, the lack of reported earnings growth data raises questions about the quality of those beats. - REVENUE DECELERATION — Revenue growth of just 1.3% YoY is extremely modest for a company with an expensive valuation multiple. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - FCF / CASH BURN — Free cash flow is not reported in the data, leaving a critical gap in assessing the company's ability to self-fund. - INSIDER ACTIVITY — 0 insider buys versus 9 sells over the last 90 days is a notable bearish signal from those most familiar with the business.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives